Home » Stocks » CHMA

Chiasma, Inc. (CHMA)

Stock Price: $3.98 USD 0.00 (0.00%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $3.90 -0.08 (-2.01%) May 6, 6:10 PM
Market Cap 230.22M
Revenue (ttm) 1.11M
Net Income (ttm) -74.78M
Shares Out 52.23M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $3.98
Previous Close $3.98
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.80
Day's Range 3.70 - 4.05
Day's Volume 8,557,904
52-Week Range 2.77 - 7.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Chiasma, Inc. (NASDAQ: CHMA) to Amryt Pharma plc is fair to Chiasma shareholders. Und...

1 day ago - Business Wire

Chiasma (CHMA) delivered earnings and revenue surprises of -63.33% and 6.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

Amryt Pharma PLC (LON:AMYT NASDAQ:AMYT)  is to merge with fellow Nasdaq-listed biotech Chiasma Inc (NASDAQ:CHMA) through an all-share deal that will create a leading specialist in rare and orphan diseas...

Other stocks mentioned: AMYT
1 day ago - Proactive Investors

Amryt Pharma PLC (LON:AMYT NASDAQ:AMYT)  is to merge with fellow Nasdaq-listed biotech Chiasma Inc (NASDAQ:CHMA) through an all-share deal that will create a leading specialist in rare and orphan diseas...

1 day ago - Proactive Investors

Penny stocks are making big waves on Cinco De Mayo; are these 3 worth watching? The post Hot Penny Stocks to Buy?

Other stocks mentioned: DPW, FAMI
1 day ago - PennyStocks

Amryt Pharma (NASDAQ: AMYT) has agreed to acquire Chiasma Inc (NASDAQ: CHMA) in an all-stock combination. Each Chiasma shares will be exchanged for 0.396 Amryt American Depositary Shares, each represent...

1 day ago - Benzinga

Announced agreement to merge with Amryt

1 day ago - GlobeNewsWire

- Combined business will have three approved commercial products, lomitapide (Lojuxta®/Juxtapid®), metreleptin (Myalept®/ Myalepta®), octreotide (MYCAPSSA®) and a robust clinical pipeline

1 day ago - GlobeNewsWire

--93% of all patients who enrolled as a responder to MYCAPSSA ® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was ge...

1 month ago - GlobeNewsWire

Chiasma Inc (NASDAQ: CHMA) has announced new data from the MPOWERED Phase 3 trial of Mycapssa as the first oral therapy to treat acromegaly. Chiasma presented the data at the Endocrine Society's annual ...

1 month ago - Benzinga

--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related...

1 month ago - GlobeNewsWire

-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biop...

1 month ago - GlobeNewsWire

Chiasma (CHMA) delivered earnings and revenue surprises of 8.57% and -17.75%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million

2 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

2 months ago - GlobeNewsWire

Appointment provides extensive commercial-stage public company financial leadership experience Appointment provides extensive commercial-stage public company financial leadership experience

3 months ago - GlobeNewsWire

MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers

4 months ago - GlobeNewsWire

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts i...

Other stocks mentioned: BHC, PRTK
4 months ago - GuruFocus

Chiasma launched its first product, Mycapssa, on August 31, 2020. Mycapssa is the first product utilizing Chiasma's proprietary technology platform that enables oral version of previously injection-only...

4 months ago - Seeking Alpha

Today, we revisit Chiasma for the first time in over a year. This promising small-cap name recently posted some encouraging trial results and has seen a big recent insider purchase by its CEO.

5 months ago - Seeking Alpha

NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral ...

5 months ago - GlobeNewsWire

NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral ...

5 months ago - GlobeNewsWire

91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized , controlled phase of the non-inferiority trial

5 months ago - GlobeNewsWire

NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral ...

5 months ago - GlobeNewsWire

Chiasma's (CHMA) CEO Raj Kannan on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

L aunched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September

6 months ago - GlobeNewsWire

NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to peo...

6 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

6 months ago - GlobeNewsWire

Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer Mark Fitzpatrick to Step Down as President and Principal Financial O...

7 months ago - GlobeNewsWire

NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to re...

7 months ago - GlobeNewsWire

Chiasma advances U.S. commercial launch originally planned for fourth quarter Chiasma advances U.S. commercial launch originally planned for fourth quarter

8 months ago - GlobeNewsWire

NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to red...

8 months ago - GlobeNewsWire

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

MYCAPSSA® U.S. commercial launch planned for the fourth quarter

8 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

9 months ago - GlobeNewsWire

-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was mai...

9 months ago - GlobeNewsWire

The company announced the pricing of a public offering of common stock.

10 months ago - The Motley Fool

NEEDHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietar...

10 months ago - GlobeNewsWire

Chiasma (CHMA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

NEEDHAM, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietar...

10 months ago - GlobeNewsWire

Chiasma's Valuation Should Be Higher Than $5-6/Share Now That Mycapssa Is FDA Approved

10 months ago - Seeking Alpha

Investors need to pay close attention to Chiasma (CHMA) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

10 months ago - GlobeNewsWire

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

NEEDHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challenges associa...

1 year ago - GlobeNewsWire

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

FDA sets PDUFA date of June 26, 2020

1 year ago - GlobeNewsWire

MYCAPSSA ® NDA resubmitted to FDA; PDUFA decision expected mid-2020

1 year ago - GlobeNewsWire

NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic dise...

1 year ago - GlobeNewsWire

WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic dise...

1 year ago - GlobeNewsWire

About CHMA

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the ma... [Read more...]

Industry
Biotechnology
IPO Date
Jul 16, 2015
CEO
Raj Kannan
Employees
85
Stock Exchange
NASDAQ
Ticker Symbol
CHMA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Chiasma stock is "Strong Buy." The 12-month stock price forecast is 13.60, which is an increase of 241.71% from the latest price.

Price Target
$13.60
(241.71% upside)
Analyst Consensus: Strong Buy